PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
about
Checkpoint inhibitors in hematological malignanciesPD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Chimeric antigen receptor T-cell therapies for lymphoma.Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinomaHigh expression of PD-1 ligands is associated with kataegis mutational signature and APOBEC3 alterations.Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review.Targeting the programmed cell death-1 pathway in rheumatoid arthritis.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model.Epstein-Barr Virus LMP1 Mediated Oncogenicity.Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate.Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns.The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor-Based Immunotherapy.Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.Impact of Chronic Viral Infection on T-Cell Dependent Humoral Immune Response.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications.Targeting the anion exchanger 2 with specific peptides as a new therapeutic approach in B lymphoid neoplasms.HIV-related Refractory Hodgkin Lymphoma: A Case Report of Complete Response to Nivolumab.Nivolumab in recurrent/metastatic head and neck cancers.Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.Stop and go: hematopoietic cell transplantation in the era of chimeric antigen receptor T cells and checkpoint inhibitors.Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade.PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma.Over-activated PD-1/PD-L1 axis facilitates the chemoresistance of diffuse large B-cell lymphoma cells to the CHOP regimen.Challenging Standard-of-Care Paradigms in the Precision Oncology Era.Immune evasion via PD-1/PD-L1 on NK-cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.Immune checkpoint receptors: homeostatic regulators of immunity.Lymphomas driven by Epstein-Barr virus nuclear antigen-1 (EBNA1) are dependant upon Mdm2.The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas.Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system.The Role of Epstein-Barr Virus in Cervical Cancer: A Brief Update.Cardiotoxicity of immune checkpoint inhibitors.Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphomaSoluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia
P2860
Q33651495-9C2E3516-1CD3-4619-B844-F5CB03F4F684Q34550012-D2D100C2-895E-4828-8830-08A081D39CA2Q38600697-58C7B6BA-96FD-4B62-A364-80B04225ADA2Q38611235-B4E64AD2-D679-4308-B863-5B07850173CFQ38719539-9B72F815-EEC4-4FCB-955D-BC96AC58457FQ38839124-1F96A946-9BCF-4A42-A29B-11178C6AEB8CQ39189031-D3CAAD7C-54E5-4BA8-A31B-15AE837F04B0Q39344907-BEF35924-8187-4321-82D7-12778B5246A6Q39381251-B4B8C366-20F5-4ECF-992D-499ACA61F1AEQ39458392-468B423F-990B-42BE-8211-AEB33B16E2E4Q40073030-8D0561E3-61E4-45ED-9BCA-42CF7022D88BQ42352191-1E3C8BFB-F1EA-4C69-9D54-4D418BABAA0AQ43715235-EC1C9105-792E-4AA1-ADE9-B24693A3A9ABQ44209463-06D3039A-E4E6-46C2-908A-D4E371D217ABQ45325729-F5766CAC-8D92-42CC-A51B-BD7DEAEB686EQ46685856-7FF3A460-4177-4062-813C-2CF1C9193418Q47093886-83F9D72D-9B25-4C40-A534-3D5AFE751218Q47148419-9023744C-FD53-4423-9290-CE549E238640Q47221234-CC1EE54F-D06D-4EE3-B240-39C345F8B1BEQ47325431-42358C3E-9284-4D59-9DB2-06DCB3B2C81FQ47388658-7D14405B-2658-4C66-A762-D92D0D51BFE5Q47552420-45F3A181-DCCB-4958-991C-D43D5C461D7FQ47610092-F6009E12-40FC-458F-86D1-0A6DD24B9B28Q47821848-3DBD174E-48A2-47A4-A191-AB7E25A84C27Q47855599-22BF8DD9-0F55-4FFB-BDB2-26CEE7F3D6AEQ47952363-49985584-D5F7-47D7-9087-52D8289F5DF5Q48275075-B8675FB5-2445-42E6-BAEA-651E8FEA45ECQ48335504-4A7D6D99-1FA7-4F96-B429-0B557FA8875FQ49785127-81CA3F58-C1F3-420D-8A57-FCB2B1617E88Q49835188-CC6DA6F7-8F16-4993-AFD8-FE3B539404C4Q49961097-AC92D008-C2C3-42A7-8EC4-E9EED221AF8FQ52733765-BA5B0536-8E2E-44CF-92AC-A3F5075A8265Q53685582-76F6B5BD-535A-4911-8A4A-12E9D65289FAQ54228841-DF2F1823-C004-4155-839C-0AFCF61FE1E7Q54957513-8D1168AF-584C-40B3-AC9C-C9AC6F672E95Q55041727-D1581392-9B7B-46B9-B2FE-DA3F03AB0F2CQ55264382-B8C4B9BA-6049-472D-B7DC-6AED9E15E408Q55438414-02C3D7E6-327E-483C-BDAE-719910D87CFBQ58691451-7D059890-1CB8-4530-9A0D-4B1612988821Q58786066-8F6E37F3-F281-456B-AEF3-D58C9C52ABE2
P2860
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
@en
type
label
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
@en
prefLabel
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
@en
P2860
P1476
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
@en
P2093
Aaron Goodman
Sandip P Patel
P2860
P304
P356
10.1038/NRCLINONC.2016.168
P407
P577
2016-11-02T00:00:00Z